Update on the treatment of endemic hemolytic uremic syndrome. Pathogenesis and treatment of the most severe systemic complication of infections by Shiga toxin-producing Escherichia coli;Actualizacion en el tratamiento del sindrome uremico hemolitico endemico patogenesis y tratamiento de la complicacion sistemica mas grave de las infecciones por escherichia coli productor de toxina shiga

Medicina

Volumn 71, Issue 4, 2011, Pages 383-389

  Fernandez Brando, Romina J ^a   Bentancor, Leticia V ^a   Mejias, Maria Pilar ^a   Panek, Analia C ^a   Cabrera, Gabriel G ^a   Exeni, Ramon A ^b   Palermo, Marina S ^a  

^a INST DE INVEST HEMATOLOGICAS   (Argentina)

^b Hospital Municipal del Niño   (Argentina)

Author keywords

Diarrhea; Escherichia coli O157:H7; Hemolytic uremic syndrome; Shiga toxin; Treatment; Typical HUS

Indexed keywords

ACUTE KIDNEY FAILURE; ARGENTINA; CHRONIC KIDNEY FAILURE; DISEASE COURSE; ENDEMIC DISEASE; ESCHERICHIA COLI INFECTION; HEMOLYTIC UREMIC SYNDROME; HUMAN; KIDNEY GRAFT; PATHOPHYSIOLOGY; REVIEW; SHIGA TOXIN PRODUCING ESCHERICHIA COLI; MICROBIOLOGY; PATHOGENICITY;

ARGENTINA; HEMOLYTIC-UREMIC SYNDROME; HUMANS; SHIGA-TOXIGENIC ESCHERICHIA COLI;

EID: 80052311724     PISSN: 00257680     EISSN: 16699106     Source Type: Journal    
DOI: None     Document Type: Review

References (37)

1. Gasser C, Gautier E, Steck A, Siebenmann RE, Oechslin R. Hemolytic-uremic syndrome: bilateral necrosis of the renal cortex in acute acquired hemolytic anemia. Schweiz Med Wochensch 1955; 85: 905-9.
2. Gianantonio C, Vitacco M, Mendilaharzu F, Rutty A, Mendilaharzu J. The Hemolytic-Uremic Syndrome. J Pediatr 1964; 64: 478-91.
3. Gianantonio CA, Vitacco M, Mendilaharzu J, Mendilaharzu F, Rutty A. Acute renal failure in infancy and childhood. Clinical course and treatment of 41 patients. J Pediatr 1962; 61: 660-78.
4. Karmali MA, Steele BT, Petric M, Lim C. Sporadic cases of haemolytic-uraemic syndrome associated with faecal cytotoxin and cytotoxin-producing Escherichia coli in stools. Lancet 1983; 1: 619-20.
5. Repetto HA. Long-term course and mechanisms of progression of renal disease in hemolytic uremic syndrome. Kidney Int Suppl 2005; 97: S102-6.
6. Lopez EL, Devoto S, Fayad A, Canepa C, Morrow AL, Cleary TG. Association between severity of gastrointestinal prodrome and long-term prognosis in classic hemolytic-uremic syndrome. J Pediatr 1992; 120: 210-5.
7. Exeni RA. Síndrome urémico hemolítico. Manifestaciones clínicas.Tratamiento. Medicina (Buenos Aires) 2006; 66 (Supl 3): 6-10.
8. Rivas M, Miliwebsky E, Chinen I, Deza N, Leotta GA. La epidemiología del síndrome urémico hemolítico en la Argentina. Diagnóstico del agente etiológico, reservorios y rutas de transmisión. Medicina (Buenos Aires) 2006; 66 (Supl 3): 27-32.
9. Rivas M, Miliwebsky E, Chinen I, et al. The Case-Control. Study Group: Characterization and epidemiologic subtyping of Shiga toxin producing Escherichia coli strains isolated from hemolytic uremic syndrome and diarrhea cases in Argentina. Foodborne Pathg Dis 2006; 3: 88-96.
10. Comité de Nefrología de la Sociedad Argentina de Pediatría: Incidencia del Síndrome Urémico Hemolítico (SUH) en la República Argentina. Arch Argent Pediatr 1995; 93: 407-11.
11. Parma AE, Sanz ME, Blanco JE, et al. Virulence genotypes and serotypes of verotoxigenic Escherichia coli isolated from cattle and foods in Argentina. Importance in public health. Eur J Epidemiol 2000; 16: 757-62.
12. Meichtri L, Miliwebsky E, Gioffre A, et al. Shiga toxinproducing Escherichia coli in healthy young beef steers from Argentina: prevalence and virulence properties. Int J Food Microbiol 2004; 96: 189-98.
13. Chinen I, Epszteyn S, Melamed CL, et al. Shiga toxinproducing Escherichia coli O157 in beef and chicken burgers, and chicken carcasses in Buenos Aires, Argentina. Int J Food Microbiol 2009; 132: 167-71.
14. Rivas M, Sosa-Estani S, Rangel J, et al. Risk factors for sporadic ShigaToxin-producing Escherichia coli infections in children, Argentina. Emerging Infectious Diseases 2008; 14: 763-71.
15. Miliwebsky E, Deza N, Chinen I, et al. Prolonged fecal shedding of Shiga toxin-producing Escherichia coli among children attending day-care centers in Argentina. Rev Argent Microbiol 2007; 39: 90-2.
16. Fernandez-Brando RJ, Bentancor LV, Mejías MP, et al. Antibody response to Shiga toxins in Argentinean children with enteropathic Hemolytic Uremic Syndrome at acute and long-term follow-up periods. Plos One 2011; 6: e19-136.
17. Spears KJ, Roe AJ, Gally DL. A comparison of enteropathogenic and enterohaemorrhagic Escherichia coli pathogenesis. FEMS Microbiol Lett 2006; 255: 187-202.
18. Herold S, Karch H, Schmidt H. Shiga toxin-encoding bacteriophages- genomes in motion. Int J Med Microbiol 2004; 294: 115-21.
19. Friedrich AW, Bielaszewska M, Zhang WL, et al. Escherichia coli harboring Shiga toxin 2 gene variants: frequency and association with clinical symptoms. J Infect Dis 2002; 185: 74-84.
20. Johannes L, Römer W. Shiga toxins-from cell biology to biomedical applications. Nat Rev Microbiol 2010; 8: 105-16.
21. Tarr PI, Gordon CA, Chandler WL. Shiga-toxin-producing Escherichia coli and haemolytic uraemic syndrome. Lancet 2005; 365: 1073-86.
22. Ake JA, Jelacic S, Ciol MA, et al. Relative nephroprotection during Escherichia coli O157:H7 infections: association with intravenous volume expansion. Pediatrics 2005; 115: e673-80.
23. Siegler R, Oakes R. Hemolytic uremic syndrome; pathogenesis, treatment, and outcome. Curr Opin Pediatr 2005; 17: 200-4.
24. Ikeda K, Ida O, Kimoto K, Takatorige T, Nakanishi N, Tatara K. Effect of early fosfomycin treatment on prevention of hemolytic uremic syndrome accompanying Escherichia coli O157:H7 infection. Clin Nephrol 1999; 52: 357-62.
25. Zimmerhackl LB. E. coli, antibiotics, and the hemolyticuremic syndrome. N Engl J Med 2000; 342: 1990-1.
26. Wong CS, Jelacic S, Habeeb RL, Watkins SL, Tarr PI. The risk of the hemolytic-uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 infections. N Engl J Med 2000; 342: 1930-6.
27. Michael M, Elliott EJ, Craig JC, Ridley G, Hodson EM. Interventions for hemolytic uremic syndrome and thrombotic thrombocytopenic purpura: a systematic review of randomized controlled trials. Am J Kidney Dis 2009; 53: 259-72.
28. Vitacco M, Sanchez Avalos J, Gianantonio CA. Heparin therapy in the hemolytic-uremic syndrome. J Pediatr 1973; 83: 271-5.
29. Palermo MS, Exeni RA, Fernández GC. Hemolytic uremic syndrome: pathogenesis and update of interventions. Expert Rev Anti Infect Ther 2009; 7: 697-707.
30. Exeni R, Donato H, Rendo P, et al. Low levels of serum erithropoietin in children with endemic hemolytic uremic syndrome. Pediatr Nephrol 1998; 12; 226-30.
31. Pape L, Ahlenstiel T, Kreuzer M, et al. Early erythropoietin reduced the need for red blood cell transfusion in childhood hemolytic uremic syndrome-a randomized prospective pilot trial. Pediatr Nephrol 2009; 24: 1061-4.
32. Valles PG, Pesle S, Piovano L, et al. Postdiarrheal Shiga toxin-mediated hemolytic uremic syndrome similar to septic shock. Medicina (Buenos Aires) 2005; 65: 395-401.
33. Cobenas CJ, Alconcher LF, Spizzirri AP, Rahman RC. Long-term follow-up of Argentinean patients with hemolytic uremic syndrome who had not undergone dialysis. Pediatr Nephrol 2007; 22: 1343-7.
34. Paton AW, Morona R, Paton JC. Neutralization of Shiga toxins Stx1, Stx2c, and Stx2e by recombinant bacteria expressing mimics of globotriose and globotetraose. Infect Immun 2001; 69: 1967-70.
35. Nishikawa K, Matsuoka K, Watanabe M, et al. Identification of the optimal structure required for a Shiga toxin neutralizer with oriented carbohydrates to function in the circulation. J Infect Dis 2005; 191: 2097-105.
36. Silberstein C, Copeland DP, Chiang W, Repetto HA, Ibarra C. A Glucosylceramide synthase inhibitor prevents the cytotoxic effects of Shiga Toxin-2 on human renal tubular epithelial cells. J Epithel Biol Pharmacol 2009; 1: 71-5.
37. Mukherjee J, Chios K, Fishwild D, et al. Human Stx2-specific monoclonal antibodies prevent systemic complications of Escherichia coli O157:H7 infection. Infect Immun 2002; 70: 612-9.